Compare FMC Corp (FMC) vs Kyndryl Holdings Inc (KD) Price & Performance

FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.

The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.

Kyndryl (KD) trades at $11.84, up 1.98% today, with a bearish technical signal and mixed earnings. Recent quarters show volatility with two misses, but 2025 marked a return to profitability with $252M net income. Cash flow improved to $236M, though revenue declined to $15.1B. The stock faces headwinds from legal investigations and internal control concerns highlighted in recent news.

Outlook: Attractive valuation metrics (P/E 13.79, EV/EBITDA 3.11) and analyst consensus target of $14.33 suggest 21% upside. Risks include ongoing legal scrutiny, revenue contraction, and high debt levels. Improved cash flow and partnerships with Microsoft/AWS support a cautious bullish case if execution stabilizes.